Mara Goldstein
Stock Analyst at Mizuho
(2.62)
# 2,134
Out of 4,734 analysts
74
Total ratings
41.82%
Success rate
5.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Outperform | $7 → $9 | $5.39 | +66.98% | 6 | Dec 19, 2024 | |
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $7.39 | +333.02% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $14.14 | +197.03% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $20.45 | +144.50% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $13.67 | +229.19% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $73.47 | +4.80% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.90 | +268.42% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.32 | +506.06% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $2.46 | +387.80% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $5.88 | +410.20% | 4 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $0.90 | +563.72% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $5.22 | -32.95% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.29 | +4,095.80% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $2.12 | +843.40% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $96.24 | +35.08% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $0.87 | +129.57% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $2.19 | +447.95% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.57 | +1,478.95% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $45.82 | -56.35% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.82 | +603.81% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $24.61 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $4.91 | +185.13% | 1 | Oct 12, 2017 |
Verastem
Dec 19, 2024
Maintains: Outperform
Price Target: $7 → $9
Current: $5.39
Upside: +66.98%
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $7.39
Upside: +333.02%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $14.14
Upside: +197.03%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $20.45
Upside: +144.50%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $13.67
Upside: +229.19%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $73.47
Upside: +4.80%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.90
Upside: +268.42%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.32
Upside: +506.06%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $2.46
Upside: +387.80%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $5.88
Upside: +410.20%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $0.90
Upside: +563.72%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $5.22
Upside: -32.95%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.29
Upside: +4,095.80%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $2.12
Upside: +843.40%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $96.24
Upside: +35.08%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $0.87
Upside: +129.57%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $2.19
Upside: +447.95%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.57
Upside: +1,478.95%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $45.82
Upside: -56.35%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.82
Upside: +603.81%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $24.61
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $4.91
Upside: +185.13%